[4-(4-Ethoxyphenyl)phenyl]methanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-(4-Ethoxyphenyl)phenyl]methanamine
• 化学式: C₁₅H₁₇NO
• mdl: MFCD05980854
• 分子量: 227.3
• InChiKey: UEMXSPHCEUDCST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
  申请人：Cook Caroline Mary

  公开号：US20080275078A1

  公开（公告）日：2008-11-06

  The invention provides a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-3 alkyl, C 1-3 fluoroalkyl, or —CH 2 CH 2 OH; R 2 is hydrogen, methyl or C 1 fluoroalkyl; R 3 is of sub-formula (aa) or (bb): wherein Y is NCONH 2 and n 1 is 0 or 1; R 4 is H; and R 5 is a group of the sub-formula (x), (y), (y1) or (z): These compounds are PDE4 inhibitors.
• POLYMER/LIQUID CRYSTAL COMPOSITE AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME
  申请人：Semiconductor Energy Laboratory Co., LTD.

  公开号：US20150212348A1

  公开（公告）日：2015-07-30

  The occurrence of a defective orientation of a polymer/liquid crystal composite is suppressed. In addition, the occurrence of defective display of a liquid crystal display device including the polymer/liquid crystal composite is suppressed. In the polymer/liquid crystal composite exhibiting a blue phase, a plurality of domains are included and defective orientations easily occur at boundaries between the domains. Thus, by lowering orientation periodicities at boundaries between the domains, a defect-free orientation to high orientation periodicities at the boundary between adjacent domains can be obtained. Specifically, the polymer/liquid crystal composite exhibiting the blue phase includes the plurality of domains each of which has a size of 3 μm or less.
• US9625776B2
  申请人：——

  公开号：US9625776B2

  公开（公告）日：2017-04-18
• [EN] PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS<br/>[FR] COMPOSES DE PYRAZOLO[3,4-B] PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PDE4
  申请人：GLAXO GROUP LTD

  公开号：WO2005090354A1

  公开（公告）日：2005-09-29

  The invention provides a compound of formula (I) or a salt thereof: formula (I) wherein: R1 is C1-3alkyl, C1-3fluoroalkyl, or -CH2CH2OH; R2 is a hydrogen atom (H), methyl or C1fluoroalkyl; R3 is of sub-formula (aa) or (bb): formulae (aa), (bb) wherein Y is NCONH2 and n1 is 0 or 1; R4 is H; and R5 is a group of the sub-formula (x), (y), (y1) or (z): formulae (x), (y), (y1), (z). The invention also relates to the use of these compounds or salts in therapy as inhibitors of phosphodiesterase type IV (PDE4). For example, it relates to their use in the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis, psoriasis or atopic dermatitis in a mammal such as a human.